Clinical Trial Update: FDG-PET in Advanced Melanoma [NA]

View source ↗

Summary

The trial evaluating FDG-PET imaging in advanced melanoma (NCT02236546) was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Recurrent Melanoma, Stage IIIA Melanoma | NA | Status: TERMINATED | Results posted: 2017-04-13